AR043053A1 - Ligandos del receptor vaniloide, composiciones farmaceuticas que los contienen, y metodos de preparacion del compuesto - Google Patents

Ligandos del receptor vaniloide, composiciones farmaceuticas que los contienen, y metodos de preparacion del compuesto

Info

Publication number
AR043053A1
AR043053A1 ARP030103783A ARP030103783A AR043053A1 AR 043053 A1 AR043053 A1 AR 043053A1 AR P030103783 A ARP030103783 A AR P030103783A AR P030103783 A ARP030103783 A AR P030103783A AR 043053 A1 AR043053 A1 AR 043053A1
Authority
AR
Argentina
Prior art keywords
nrarh
nrarg
alkyl
nra
org
Prior art date
Application number
ARP030103783A
Other languages
English (en)
Inventor
Yunxin Y Bo
Chenera Balan
Celia Dominguez
Christopher H Fotsch
Vijay Keshav Gore
Vu Van Ma
Mark Henry Norman
Vassil I Ognyanov
Yi-Xin Qian
Xianghong Wang
Shimin Xu
Ning Xi
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of AR043053A1 publication Critical patent/AR043053A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/30—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Otolaryngology (AREA)
  • Obesity (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Bencimidazoles terapéuticos y composiciones que los contengan, son útiles para el tratamiento de dolores agudos, inflamatorios o neuropáticos, dolores dentales, dolores de cabeza en general, migrana, dolor de cabeza "en racimo" (cluster headache), síndromes mixtos vasculares y no vasculares, dolor de cabeza por tensión, inflamación general, artritis, enfermedades reumáticas, osteoartritis, enfermedad inflamatoria intestinal, trastornos oculares inflamatorios, trastornos vesiculares inflamatorios o inestables, psoriasis, molestias de la piel con componentes inflamatorios, patologías inflamatorias crónicas, dolor inflamatorio e hiperalgesia y alodinia asociadas, dolor neuropático e hiperalgesia y alodinia asociadas, dolor neuropático diabético, causalgia, dolor mantenido por el simpático, síndromes de deaferenciación, asma, danos o disfunciones de tejidos epiteliales, herpes simplex, trastornos de motilidad visceral en las regiones respiratoria, genitourinaria, gastrointestinal o vascular, heridas, quemaduras, reacciones alérgicas de la piel, prurito, vitiligo, trastornos gastrointestinales generales, úlceras gástricas, úlceras duodenales, diarrea, lesiones gástricas inducidas por agentes necrotizantes, crecimiento del cabello, rinitis vasomotora o alérgica, trastornos bronquiales o trastornos de la vesícula. Reivindicación 1: Un compuesto que tiene la estructura de la fórmula (1) o cualquiera de sus sales farmacéuticamente aceptables, donde L1 es una cadena saturada, insaturada o parcialmente saturada de 1, 2 ó 3 átomos de carbono sustituida en cada posición abierta por R2; L2 es una cadena saturada, insaturada o parcialmente saturada de 1, 2 ó 3 átomos de carbono sustituida en cada posición abierta por R2'; donde la cantidad combinada de átomos de carbono en las cadenas L1 y L2 es 4 ó 5; donde, cuando L1 es una cadena de un carbono y tanto Q1 como Q2 son N, L1 es carbonilo, y cuando L2 es una cadena de un carbono y tanto Q1 como Q2 son N, L2 es carbonilo; m es independientemente en cada instancia 0, 1 ó 2; Q1 es N ó C(R2); Q2 es N ó C(R2); donde al menos uno de Q1 y Q2 es N; Q3 es N ó C(R5); Q4 es N ó C(R6); Q5 es N ó C(R6'); Q6 es N ó C(R5'); R1 es H ó -(C(R2)(R2))m-Rg; R2 es, independientemente, en cada instancia, H, alquilo C1-8, haloalquilo C1-4, -O(alquilo C1-7), -N(alquilo C1-7)Ra, ó un alquilo C1 6 sustituido por 1, 2 ó 3 sustituyentes seleccionados de halo, ciano, -ORa, -OC(=O)Rb, -SRa, -S(=O)Rb, -S(=O)2Rb, -S(=O)2NRaRa, -NRaRa, -N(Ra)C(=O)Rb, -N(Ra)C(=O)ORb, -N(Ra)C(=O)NRaRa, -N(Ra)C(=NRa)NRaRa, -N(Ra)S(=O)2Rb, -NRaalquil C2-6-NRaRa y -NRaalquil C2-6-ORa; donde cualesquiera dos grupos R2 geminales pueden ser, adicionalmente, oxo; R2' es, independientemente, en cada instancia, H, alquilo C1-8, haloalquilo C1-4, -O(alquilo C1-7), -N(alquilo C1-7)Ra, ó un alquilo C1-6 sustituido por 1, 2 ó 3 sustituyentes seleccionados de halo, ciano, -ORa, -OC(=O)Rb, -SRa, -S(=O)Rb, -S(=O)2Rb, -S(=O)2NRaRa, -NRaRa, -N(Ra)C(=O)Rb, -N(Ra)C(=O)ORb, -N(Ra)C(=O)NRaRa, -N(Ra)C(=NRa)NRaRa, -N(Ra)S(=O)2Rb, -NRaalquil C2-6NRaRa y -NRaalquil C2-6ORa; donde cualesquiera dos grupos R2' geminales pueden ser, adicionalmente, oxo; R4 es fenilo ó naftilo, donde el fenilo y el naftilo son sustituidos por 1, 2, 3 ó 4 sustituyentes seleccionados de Rc, Re, halo, haloalquilo C1-4, ciano, nitro, -C(=O)Re, -C(=O)ORh, -C(=O)NRaRh, -C(=NRa)NRaRh, -ORh, -OC(=O)Re, -OC(=O)NRaRh, -OC(=O)N(Ra)S(=O)2Re, -Oalquil C2-6NRaRh, -Oalquil C2-6ORh, -SRe, -S(=O)Re, -S(=O)2Re, -S(=O)2NRaRh, -S(=O)2N(Ra)C(=O)Re, -S(=O)2N(Ra)C(=O)ORh, -S(=O)2n(Ra)C(=O)NRaRh, -NRaRh, -N(Ra)C(=O)Re, -N(Ra)C(=O)ORh, -N(Ra)C(=O)NRaRh, -N(Ra)C(=NRa)NRaRh, -N(Ra)S(=O)2Re, -N(Ra)S(=O)2NRaRh, -NRaalquil C2-6NRaRh, -NRaalquil C2-6ORh, -C(=O)Rg, -C(=O)ORg, -C(=O)NRaRg, -C(=NRa)NRaRg, -ORg, -OC(=O)Rg, -OC(=O)NRaRg, -OC(=O)N(Ra)S(=O)2Rg, -OC(=O)N(Rg)S(=O)2Re, -Oalquil C2-6NRaRg, -Oalquil C2-6ORg, -SRg, -S(=O)Rg, -S(=O)2Rg, -S(=O)2NRaRg, -S(=O)2N(Rg)C(=O)Re, -S(=O)2N(Ra)C(=O)Rg, -S(=O2)N(Rg)C(=O)ORh, -S(=O)2N(Ra)C(=O)Rg, -S(=O)2N(Rg)C(=O)NRaRh, -S(=O2)N(Ra)C(=O)NRaRg, -NRaRg, -N(Rg)C(=O)Re, -N(Ra)C(=O)Rg, -N(Rg)C(=O)ORh, -N(Ra)C(=O)ORg, -N(Rg)C(=O)NRaRh, -N(Ra)C(=O)NRaRg, -N(Rg)C(=NRa)NRaRh, -N(Ra)C(=NRa)NRaRg, -N(Rg)S(=O)2Re, -N(Ra)S(=O)2Rg, -N(Rg)S(=O2)NRaRh, -N(Ra)S(=O)2NRaRg, -NRhalquil C2-6NRaRg, -NRaalquil C2-6NRaRg, -NRgalquil C2-6ORh y -NRaalquil C2-6ORg; ó bien R4 es Rc sustituido por 0, 1, 2, 3 ó 4 sustituyentes que se seleccionan de Rc, Re, halo, haloalquilo C1-4, ciano, nitro, -C(=O)Re, -C(=O)ORh, -C(=O)NRaRh, -C(=NRa)NRaRh, -ORh, -OC(=O)Re, -OC(=O)NRaRh, -OC(=O)N(Ra)S(=O)2Re, -Oalquil C2-6NRaRh, -Oalquil C2-6ORh, -SRe, -S(=O)Re, -S(=O)2Re, -S(=O)2NRaRh, -S(=O)2N(Ra)C(=O)Re, -S(=O)2N(Ra)C(=O)ORh, -S(=O)2N(Ra)C(=O)NRaRh, -NRaRh, -N(Ra)C(=O)Re, -N(Ra)C(=O)ORh, -N(Ra)C(=O)NRaRh, -N(Ra)C(=NRa)NRaRh, -N(Ra)S(=O)2Re, -N(Ra)S(=O)2NRaRh, -NRaalquil C2-6NRaRh, -NRaalquil C2-6ORh, -C(=O)Rg, -C(=O)ORg, -C(=O)NRaRg, -C(=NRa)NRaRg, -ORg, -OC(=O)Rg, -OC(=O)NRaRg, -OC(=O)N(Ra)S(=O)2Rg, -OC(=O)N(Rg)S(=O)2Re, -Oalquil C2-6NRaRg, -Oalquil C2-6ORg, -SRg, -S(=O)Rg, -S(=O)2Rg, -S(=O2)NRaRg, - S(=O)2N(Rg)C(=O)Re, -S(=O)2N(Ra)C(=O)Rg, -S(=O2)N(Rg)C(=O)ORh, -S(=O)2N(Ra)C(=O)ORg, -S(=O)2N(Rg)C(=O)NRaRh, -S(=O)2N(Ra)C(=O)NRaRg, -NRaRg, -N(Rg)C(=O)Re, -N(Ra)C(=O)Rg, -N(Rg)C(=O)ORh, -N(Ra)C(=O)ORg, -N(Rg)C(=O)NRaRh, -N(Ra)C(=O)NRaRg, -N(Rg)C(=NRa)NRaRh, -N(Ra)C(=NRa)NRaRg, -N(Rg)S(=O)2Re, -N(Ra)S(=O)2Rg, -N(Rg)S(=O)2NRaRh, -N(Ra)S(=O)2NRaRg, -NRhalquil C2-6NRaRg, -NRaalquil C2-6NRaRg, -NRgalquil C2-6ORh y -NRaalquil C2-6ORg; R5 es H, Re, haloalquilo C1-4, halo, ciano, -C(=O)Re, -C(=O)ORe, -C(=O)NReRa, -C(=NRa)NRhRa, -ORh, -OC(=O)Re, -OC(=O)NRaRh, -OC(=O)N(Ra)S(=O)2Re, -Oalquil C2-6NRaRh, -Oalquil C2-6ORh, -SRh, -S(=O)Re, -S(=O)2Re, -S(=O2)NRaRh, -S(=O)2N(Ra)C(=O)Re, -S(=O)2N(Ra)C(=O)OR3, -S(=O)2N(Ra)C(=O)NRaRh, -NRaRh, -N(Ra)C(=O)Re, -N(Ra)C(=O)ORe, -N(Ra)C(=O)NRaRh, -N(Ra)C(=NRa)NRaRh, -N(Ra)S(=O)2Re, -N(Ra)S(=O)2NRaRh, -NRaalquil C2-6NRaRh, -NRaalquil C2-6ORh, -C(=O)Rg, -C(=O)ORg, -C(=O)NRgRa, -C(=NRa)NRaRg, -ORg, -OC(=O)Rg, -OC(=O)NRaRg, -OC(=O)N(Ra)S(=O)2Rg, -Oalquil C2-6NRaRg, -Oalquil C2-6ORg, -SRg, -S(=O)Rg, -S(=O)2Rg, -S(=O)2NRaRg, -S(=O)2N(Ra)C(=O)Rg, -S(=O)2N(Ra)C(=O)ORg, -S(=O)2N(Ra)C(=O)NRaRg, -NRaRg, -N(Ra)C(=O)Rg, -N(Ra)C(=O)ORg, -N(Ra)C(=O)NRaRg, -N(Ra)C(=NRa)NRaRg, -N(Ra)S(=O)2Rg, -N(Ra)S(=O)2NRaRg, -NRaalquil C2-6NRaRg ó -NRaalquil C2-6ORg; ó bien R5 es una cadena cerrada, saturada o insaturada, monocíclica de 5, 6 ó 7 miembros o bicíclica de 6, 7, 8, 9, 10 u 11 miembros que contiene 0, 1, 2, 3 ó 4 átomos seleccionados de N, O y S, donde los átomos de carbono de la cadena cerrada son sustituidos por 0, 1 ó 2 grupos oxo y la cadena cerrada es sustituida por 0, 1, 2, 3 ó 4 sustituyentes seleccionados de Re, haloalquilo C1-4, halo, ciano, nitro, -C(=O)Re, -C(=O)ORe, -C(=O)NReRa, -C(=NRa)NRhRa, -ORh, -OC(=O)Re, -OC(=O)NRaRh, -OC(=O)N(Ra)S(=O)2Re, -Oalquil C2-6NRaRh, -Oalquil C2-6ORh, -SRh, -S(=O)Re, -S(=O)2Re, -S(=O)2NRaRh, -S(=O)2N(Ra)C(=O)Re, -S(=O)2N(Ra)C(=O)ORe, -S(=O)2N(Ra)C(=O)NRaRh, -NRaRh, -N(Ra)C(=O)Re, -N(Ra)C(=O)ORe, -N(Ra)C(=O)NRaRh, -N(Ra)C(=NRa)NRaRh, -N(Ra)S(=O)2Re, -N(Ra)S(=O)2NRaRh, -NRaalquil C2-6NRaRh, -NRaalquil C2-6ORh, -C(=O)Rg, -C(=O)ORg, -C(=O)NRgRa, -C(=NRa)NRaRg, -ORg, -OC(=O)Rg, -OC(=O)NRaRg, -OC(=O)N(Ra)S(=O)2Rg, -Oalquil C2-6NRaRg, -Oalquil C2-6ORg, -SRg, -S(=O)Rg, -S(=O2)Rg, -S(=O)2NRaRg, -S(=O)2N(Ra)C(=O)Rg, -S(=O)2N(Ra)C(=O)ORg, -S(=O)2N(Ra)C(=O)NRaRg, -NRaRg, -N(Ra)C(=O)Rg, -N(Ra)C(=O)ORg, -N(Ra)C(=O)NRaRg, -N(Ra)C(=NRa)NRaRg, -N(Ra)S(=O)2Rg, -N(Ra)S(=O)2NRaRg, -NRaalquil C2-6NRaRg y -NRaalquil C2-6ORg; R5' es H, Re, haloalquilo C1-4, halo, ciano, -C(=O)Re, -C(=O)ORe, -C(=O)NReRa, -C(=NRa)NRhRa, -ORh, -OC(=O)Re, -OC(=O)NRaRh, -OC(=O)N(Ra)S(=O)2Re, -Oalquil C2-6NRaRh, -Oalquil C2-6ORh, -SRh, -S(=O)Re, -S(=O)2Re, -S(=O2)NRaRh, -S(=O)2N(Ra)C(=O)Re, -S(=O)2N(Ra)C(=O)ORe, -S(=O)2N(Ra)C(=O)NRaRh, -NRaRh, -N(Ra)C(=O)Re, -N(Ra)C(=O)ORe, -N(Ra)C(=O)NRaRh, -N(Ra)C(=NRa)NRaRh, -N(Ra)S(=O)2Re, -N(Ra)S(=O)2NRaRh, -NRaalquil C2-6NRaRh, -NRaalquil C2-6ORh, -C(=O)Rg, -C(=O)ORg, -C(=O)NRgRa, -C(=NRa)NRaRg, -ORg, -OC(=O)Rg, -OC(=O)NRaRg, -OC(=O)N(Ra)S(=O)2Rg, -Oalquil C2-6NRaRg, -Oalquil C2-6ORg, -SRg, -S(=O)Rg, -S(=O)2Rg, -S(=O)2NRaRg, -S(=O)2N(Ra)C(=O)Rg, -S(=O)2N(Ra)C(=O)ORg, -S(=O)2N(Ra)C(=O)NRaRg, -NRaRg, -N(Ra)C(=O)Rg, -N(Ra)C(=O)ORg, -N(Ra)C(=O)NRaRg, -N(Ra)C(=NRa)NRaRg, -N(Ra)S(=O)2Rg, -N(Ra)S(=O)2NRaRg, -NRaalquil C2-6NRaRg ó -NRaalquil C2-6ORg; ó bien R5' es una cadena cerrada, saturada o insaturada, monocíclica de 5, 6 ó 7 miembros o bicíclica de 6, 7, 8, 9, 10 u 11 miembros que contiene 0, 1, 2, 3 ó 4 átomos seleccionados de N, O y S, donde los átomos de carbono de la cadena cerrada son sustituidos por 0, 1 ó 2 grupos oxo y la cadena cerrada es sustituida por 0, 1, 2, 3 ó 4 sustituyentes que se seleccionan de Re, haloalquilo C1-4, halo, ciano, nitro, -C(=O)Re, -C(=O)ORe, -C(=O)NReRa, -C(=NRa)NRhRa, -ORh, -OC(=O)Re, -OC(=O)NRaRh, -OC(=O)N(Ra)S(=O)2Re, -Oalquil C2-6NRaRh, -Oalquil C2-6ORh, -SRh, -S(=O)Re, -S(=O)2Re, -S(=O)2NRaRh, -S(=O)2N(Ra)C(=O)Re, -S(=O)2N(Ra)C(=O)ORe, -S(=O)2N(Ra)C(=O)NRaRh, -NRaRh, -N(Ra)C(=O)Re, -N(Ra)C(=O)ORe, -N(Ra)C(=O)NRaRh, -N(Ra)C(=NRa)NRaRh, -N(Ra)S(=O)2Re, -N(Ra)S(=O)2NRaRh, -NRaalquil C2-6NRaRh, -NRaalquil C2-6ORh, -C(=O)Rg, -C(=O)ORg, -C(=O)NRgRa, -C(=NRa)NRaRg, -ORg, -OC(=O)Rg, -OC(=O)NRaRg, -OC(=O)N(Ra)S(=O)2Rg, -Oalquil C2-6NRaRg, -Oalquil C2-6ORg, -SRg, -S(=O)Rg, -S(=O)2Rg, -S(=O)2NRaRg, -S(=O)2N(Ra)C(=O)Rg, -S(=O)2N(Ra)C(=O)ORg, -S(=O2)N(Ra)C(=O)NRaRg, -NRaRg, -N(Ra)C(=O)Rg, -N(Ra)C(=O)ORg, -N(Ra)C(=O)NRaRg, -N(Ra)C(=NRa)NRaRg, -N(Ra)S(=O)2Rg, -N(Ra)S(=O)2NRaRg, -NRaalquil C2-6NRaRg y -NRaalquil C2-6ORg; R6 es H, haloalquilo C1-4, halo, ciano, -C(=O)Rb, -C(=O)ORb, -C(=O)NRaRa, -C(=NRa)NRaRa, -OH, -Oalquilo C2-6, -OC(=O)Rb, -OC(=O)NRaRa, -OC(=O)N(Ra)S(=O)2Rb, -Oalquil C2-6NRaRa, -Oalquil C2-6Ra, -SRa, -S(=O)Rb, -S(=O)2Rb, -S(=O)2NRaRa, -S(=O)2n(Ra)C(=O)Rb, -S(=O)2N(Ra)C(=O)ORb, -S(=O)2N(Ra)C(=O)NRaRa, -NRaRb, -N(Ra)C(=O)Rb, -N(Ra)
ARP030103783A 2002-10-17 2003-10-17 Ligandos del receptor vaniloide, composiciones farmaceuticas que los contienen, y metodos de preparacion del compuesto AR043053A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US41979102P 2002-10-17 2002-10-17

Publications (1)

Publication Number Publication Date
AR043053A1 true AR043053A1 (es) 2005-07-13

Family

ID=32108141

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP030103783A AR043053A1 (es) 2002-10-17 2003-10-17 Ligandos del receptor vaniloide, composiciones farmaceuticas que los contienen, y metodos de preparacion del compuesto

Country Status (10)

Country Link
US (2) US7582761B2 (es)
EP (1) EP1551811A1 (es)
JP (1) JP2006505570A (es)
AR (1) AR043053A1 (es)
AU (1) AU2003301436A1 (es)
CA (1) CA2501539A1 (es)
MX (1) MXPA05003948A (es)
PL (1) PL377215A1 (es)
TW (1) TW200418807A (es)
WO (1) WO2004035549A1 (es)

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100777169B1 (ko) 2001-01-29 2007-11-16 시오노기세이야쿠가부시키가이샤 5-메틸-1-페닐-2-(1ｈ)-피리돈을 활성 성분으로서함유하는 의약 제제
US7582635B2 (en) 2002-12-24 2009-09-01 Purdue Pharma, L.P. Therapeutic agents useful for treating pain
SE0301446D0 (sv) * 2003-05-16 2003-05-16 Astrazeneca Ab New Compounds
EP1627869B1 (en) 2003-05-20 2012-05-02 Ajinomoto Co., Inc. Vanilloid receptor modulators
TWI287010B (en) * 2003-06-12 2007-09-21 Euro Celtique Sa Therapeutic agents useful for treating pain
ES2568769T3 (es) 2003-07-30 2016-05-04 Xenon Pharmaceuticals Inc. Derivados de piperazina y su uso como agentes terapéuticos
SG145700A1 (en) * 2003-07-30 2008-09-29 Xenon Pharmaceuticals Inc Pyridyl derivatives and their use as therapeutic agents
GB0319150D0 (en) * 2003-08-14 2003-09-17 Glaxo Group Ltd Novel compounds
NZ552093A (en) * 2004-06-17 2009-06-26 Wyeth Corp Processes for preparing gonadotropin releasing hormone receptor antagonists
MXPA06014798A (es) 2004-06-17 2007-06-22 Wyeth Corp Antagonistas del receptor de hormona para liberar gonadotropina.
EP1768959A2 (en) * 2004-06-28 2007-04-04 Janssen Pharmaceutica N.V. Hetero isonipecotic modulators of vanilloid vr1 receptor
CA2580762A1 (en) 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as therapeutic agents
BRPI0515483A (pt) 2004-09-20 2008-07-22 Xenon Pharmaceuticals Inc derivados heterocìclicos para o tratamento de doenças mediadas por enzimas estearoil-coa desaturase
AR051294A1 (es) 2004-09-20 2007-01-03 Xenon Pharmaceuticals Inc Derivados heterociclicos y su uso como inhibidores de la estearoil-coa desaturasa
AU2005286648A1 (en) 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as stearoyl-CoA desaturase inhibitors
WO2006101521A2 (en) 2004-09-20 2006-09-28 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as stearoyl-coa desaturase inhibitors
BRPI0515478A (pt) 2004-09-20 2008-07-22 Xenon Pharmaceuticals Inc derivados heterocìclicos e seu uso como mediadores de estearoil-coa-desaturase
MX2007003325A (es) 2004-09-20 2007-06-05 Xenon Pharmaceuticals Inc Derivados heterociclicos y su uso como inhibidores estearoil-coa-desaturasa.
CA2580845A1 (en) 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Pyridazine derivatives for inhibiting human stearoyl-coa-desaturase
SE0402284D0 (sv) * 2004-09-21 2004-09-21 Astrazeneca Ab New heterocyclic amides
WO2006044527A1 (en) * 2004-10-15 2006-04-27 Amgen Inc. Imidazole derivatives as vanilloid receptor ligands
KR101099303B1 (ko) * 2005-01-28 2011-12-26 주식회사 대웅제약 신규한 벤조이미다졸 유도체 및 이를 함유하는 약제학적조성물
KR20060087386A (ko) 2005-01-28 2006-08-02 주식회사 대웅제약 신규 벤조이미다졸 유도체 및 이를 함유하는 약제학적조성물
TWI370820B (en) * 2005-04-27 2012-08-21 Takeda Pharmaceutical Fused heterocyclic compounds
CN101208089A (zh) 2005-06-03 2008-06-25 泽农医药公司 氨基噻唑衍生物作为人硬酯酰-CoA去饱和酶抑制剂
GB0525957D0 (en) * 2005-12-21 2006-02-01 Astrazeneca Ab Methods
UY30048A1 (es) * 2005-12-23 2007-07-31 Astrazeneca Ab Derivados sustituidos de la n,2-(1h-benzimidazol-1-il) acetamida, composiciones farmacéuticas conteniéndolos, procesos de preparación y aplicaciones
US7951829B2 (en) * 2006-05-03 2011-05-31 Janssen Pharmaceutica Nv Benzimidazole modulators of VR1
JP2009541454A (ja) * 2006-07-03 2009-11-26 ノイロサーチ アクティーゼルスカブ モノアミン再摂取阻害剤及びカリウムチャネル活性剤の併用
TWI433839B (zh) * 2006-08-11 2014-04-11 Neomed Inst 新穎的苯并咪唑衍生物290
DE602007006990D1 (de) 2006-12-07 2010-07-15 Hoffmann La Roche Spiropiperidinderivate als antagonisten des via-rezeptors
RU2009119393A (ru) 2006-12-07 2011-01-20 Ф. Хоффманн-Ля Рош Аг (Ch) Производные спиропиперидина
ES2371784T3 (es) 2006-12-08 2012-01-10 F. Hoffmann-La Roche Ag Indoles.
DE602007007512D1 (de) 2006-12-08 2010-08-12 Hoffmann La Roche Als via-rezeptor-antagonisten verwendbare indole
EP2121626A1 (en) * 2006-12-15 2009-11-25 Pfizer Products Inc. Benzimidazole derivatives
US20080153863A1 (en) 2006-12-22 2008-06-26 Caterina Bissantz Spiropiperidine derivatives
WO2008133973A1 (en) * 2007-04-27 2008-11-06 Purdue Pharma L.P. Therapeutic agents useful for treating pain
CA2756791C (en) 2007-04-27 2016-09-13 Purdue Pharma L.P. Trpv1 antagonists and uses thereof
ME00962B (me) 2007-06-29 2012-06-20 Pfizer Benzimidazolski derivati
CN101925575B (zh) 2008-01-28 2014-06-18 株式会社爱茉莉太平洋 作为香草酸受体拮抗剂的化合物、其异构体或其药物学可接受的盐、及包含这些化合物的药物组合物
JP5372138B2 (ja) * 2008-04-18 2013-12-18 テウン ファーマシューティカル カンパニー，リミテッド 新規ベンゾオキサジンベンズイミダゾール誘導体、これを含む薬学組成物およびこの用途
CN102137851B (zh) 2008-07-02 2014-08-27 株式会社爱茉莉太平洋 作为香草素受体拮抗剂的化合物、其异构体或其药学可接受的盐以及包含它们的药物组合物
DE102008039082A1 (de) 2008-08-21 2010-02-25 Bayer Schering Pharma Aktiengesellschaft Azabicyclisch-substituierte 5-Aminopyrazole und ihre Verwendung
US8703962B2 (en) * 2008-10-24 2014-04-22 Purdue Pharma L.P. Monocyclic compounds and their use as TRPV1 ligands
US8759362B2 (en) * 2008-10-24 2014-06-24 Purdue Pharma L.P. Bicycloheteroaryl compounds and their use as TRPV1 ligands
US8546388B2 (en) * 2008-10-24 2013-10-01 Purdue Pharma L.P. Heterocyclic TRPV1 receptor ligands
CA2750577A1 (en) * 2008-12-03 2010-06-10 Presidio Pharmaceuticals, Inc. Inhibitors of hcv ns5a
EP2414328B1 (en) 2009-04-02 2021-05-26 Merck Serono S.A. Dihydroorotate dehydrogenase inhibitors
WO2010135568A1 (en) 2009-05-22 2010-11-25 Exelixis, Inc. Benzoxazepines as inhibitors of mtor and their use to treat cancer
US8680098B2 (en) 2010-03-05 2014-03-25 Janssen Pharmaceutica, Nv Substituted aza-bicyclic imidazole derivatives useful as TRPM8 receptor modulators
SG185515A1 (en) 2010-05-13 2012-12-28 Amgen Inc Nitrogen heterocyclic compounds useful as pde10 inhibitors
US8946230B2 (en) 2010-05-13 2015-02-03 Amgen Inc. Aryl- and heteroaryl- nitrogen-heterocyclic compounds as PDE10 inhibitors
US8921373B2 (en) 2010-06-22 2014-12-30 Shionogi & Co., Ltd. Compounds having TRPV1 antagonistic activity and uses thereof
US9133160B2 (en) 2010-10-01 2015-09-15 Bristol-Meyers Squibb Company Substituted benzimidazole and imidazopyridine compounds useful as CYP17 modulators
KR101293384B1 (ko) 2010-10-13 2013-08-05 주식회사 대웅제약 신규 피리딜 벤조옥사진 유도체, 이를 포함하는 약학 조성물 및 이의 용도
EP2709609B1 (en) 2011-05-17 2017-10-04 Shionogi & Co., Ltd. Heterocyclic compounds
JP6463631B2 (ja) * 2011-06-09 2019-02-06 ライゼン・ファーマシューティカルズ・エスアー Ｇｐｒ−１１９のモジュレータとしての新規化合物
PT2723732T (pt) 2011-06-22 2017-02-17 Purdue Pharma Lp Antagonistas de trpv1 incluindo substituinte di-hidroxilo e suas utilizações
WO2014127350A1 (en) * 2013-02-18 2014-08-21 The Scripps Research Institute Modulators of vasopressin receptors with therapeutic potential
US9938292B2 (en) * 2014-03-24 2018-04-10 Guangdong Zhongsheng Pharmaceutical Co., Ltd Quinoline derivatives as SMO inhibitors
CN110872289A (zh) 2015-04-10 2020-03-10 百济神州(北京)生物科技有限公司 作为IDO1和/或TDO抑制剂的新颖的8-取代的咪唑并[1,5-a]吡啶
CA2937365C (en) 2016-03-29 2018-09-18 F. Hoffmann-La Roche Ag Granulate formulation of 5-methyl-1-phenyl-2-(1h)-pyridone and method of making the same
US10882856B2 (en) 2016-09-24 2021-01-05 Beigene, Ltd. 5 or 8-substituted imidazo [1,5-a] pyridines as selective inhibitors of indoleamine and/or tryptophane 2,3-dioxygenases
WO2019079578A1 (en) * 2017-10-19 2019-04-25 Amgen Inc. BENZIMIDAZOLE DERIVATIVES AND USES THEREOF
EP3703684A1 (en) 2017-10-30 2020-09-09 The Scripps Research Institute Small molecule inhibitors of cancer stem cells and mesenchymal cancer types
CN111386114A (zh) * 2017-11-25 2020-07-07 百济神州有限公司 作为吲哚胺2,3-双加氧酶的选择性抑制剂的新颖苯并咪唑
WO2020210597A1 (en) * 2019-04-11 2020-10-15 Amgen Inc. Benzimidazole derivatives and their uses
CN113891880A (zh) * 2019-05-22 2022-01-04 百济神州有限公司 作为吲哚胺2,3-双加氧酶的选择性抑制剂的酰胺取代的咪唑并化合物
WO2023017094A1 (en) 2021-08-10 2023-02-16 Syngenta Crop Protection Ag 2,2-difluoro-5h-[1,3]dioxolo[4,5-f]isoindol-7-one derivatives as pesticides
DE102022104759A1 (de) 2022-02-28 2023-08-31 SCi Kontor GmbH Co-Kristall-Screening Verfahren, insbesondere zur Herstellung von Co-Kristallen

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4093726A (en) * 1976-12-02 1978-06-06 Abbott Laboratories N-(2-benzimidazolyl)-piperazines
NZ321575A (en) * 1995-10-30 1999-05-28 Janssen Pharmaceutica Nv 1-(1,2-disubstituted piperidinyl)-4- substituted piperazine derivatives
AU2076299A (en) * 1998-01-30 1999-08-16 Meiji Seika Kaisha Ltd. Phenylpiperazine derivatives as integrin alphavbeta3 antagonists
CZ300148B6 (cs) * 1998-11-27 2009-02-25 Abbott Gmbh & Co. Kg Derivát substituovaného benzimidazolu, zpusob jeho prípravy a jeho použití
MXPA02000120A (es) * 1999-06-28 2002-07-02 Janssen Pharmaceutica Nv Inhibidores de la replicacion del virus sincitial respiratorio.
AU8066701A (en) * 2000-07-20 2002-02-05 Neurogen Corp Capsaicin receptor ligands
US7074794B2 (en) * 2000-08-10 2006-07-11 Mitsubishi Pharma Corporation Proline derivatives and the use thereof as drugs
DE10134775A1 (de) 2001-07-06 2003-01-30 Schering Ag 1-Alkyl-2.aryl-benzimidazolderivate, deren Verwendung zur Herstellung von Arzneimitteln sowie diese Derivate enthaltende pharmazeutische Präparate
DE10135050A1 (de) 2001-07-09 2003-02-06 Schering Ag 1-Ary1-2-N-, S- oder O-substituierte Benzimidazolderivate, deren Verwendung zur Herstellung von Arzneimitteln sowie diese Derivate enthaltende pharmazeutische Präparate
EP2033951A3 (en) 2002-02-01 2009-12-23 Euro-Celtique S.A. 2-Piperazine-pyridines useful for treating pain
US7582635B2 (en) * 2002-12-24 2009-09-01 Purdue Pharma, L.P. Therapeutic agents useful for treating pain

Also Published As

Publication number Publication date
US8026241B2 (en) 2011-09-27
US7582761B2 (en) 2009-09-01
PL377215A1 (pl) 2006-01-23
CA2501539A1 (en) 2004-04-29
JP2006505570A (ja) 2006-02-16
AU2003301436A1 (en) 2004-05-04
EP1551811A1 (en) 2005-07-13
US20040152690A1 (en) 2004-08-05
US20090143575A1 (en) 2009-06-04
WO2004035549A1 (en) 2004-04-29
MXPA05003948A (es) 2005-06-17
TW200418807A (en) 2004-10-01

Similar Documents

Publication Publication Date Title
AR043053A1 (es) Ligandos del receptor vaniloide, composiciones farmaceuticas que los contienen, y metodos de preparacion del compuesto
AR049771A1 (es) Derivados de pirimidina para uso como ligandos del receptor vaniloide y su empleo en tratamientos
EP1717220A3 (en) Vanilloid receptor ligands and their use in treatments
PL375552A1 (en) Vanilloid receptor ligands and their medical applications
AR035861A1 (es) Compuestos aminoacidos biciclicos o triciclicos condensados, procedimiento de preparacion, composiciones farmaceuticas y su uso en la preparacion de medicamentos
UY28724A1 (es) Derivados de sulfonamida para el tratamiento de enfermedades
UY28721A1 (es) Derivados de sulfonamida para eltratamiento de enfermedades
JP2009502829A5 (es)
UY28280A1 (es) 2- hidroxi - 3- diaminoalcanos de benzamida
AR072937A1 (es) Derivados de piridina y pirimidina sustituida y su uso en el tratamiento de infecciones virales
CL2007002450A1 (es) Forma polimorfica i del enantiomero levogiro o dextrogiro de modafinilo; su procedimiento de preparacion; y composicion farmaceutica que los comprende (divisional solicitud 2693-03).
AR058326A1 (es) Anticuerpo monoclonal
UY28752A1 (es) Agentes terapeuticos
BRPI0619522B8 (pt) conjugados de objetivação de vetor-fosfolipídio, composição compreendendo os referidos conjugados, composição de agente de contraste para ultra-som e método para preparo de microvesícula cheia de gás compreendendo um fosfolipídio e de fabricação de conjugado de peptídeo-fosfolipídio tendo baixos níveis de tfa
ECSP056164A (es) Compuestos utiles para el tratamiento de enfermedades
AR086750A1 (es) Ligandos del receptor trpm8 y su uso en diversos tratamientos
RU98101093A (ru) Соединения, регулирующие мейоз
UY28374A1 (es) Agentes terapéuticos
AR083202A1 (es) Derivados de azabiciclo[3.1.0]hexano
WO2005033105A3 (en) Vanilloid receptor ligands and their use in treatments
WO2005072681A3 (en) Vanilloid receptor ligands and their use in treatments of inflammatory and neurotic pain.
AR057033A1 (es) Tigeciclina y metodos para preparar 9-nitrominociclina
GT200600280A (es) Composiciones y metodos para el tratamiento de sintomas relacionados con el ciclo
PE20110677A1 (es) Polimorfo b de la n-(2-aminofenil)-4-[n-(piridin-3-il) metoxicarbonilamino-metil]benzamida (ms-275)
AR061151A1 (es) Formas cristalinas de 11beta - (4 - acetilfenil) - 20, 20, 21, 21, 21 - pentafluoro - 17 - hidroxi - 19 - nor - 17alfa - pregna - 4, 9 - dien - 3 - ona, metodos para su obtencion y preparaciones farmaceuticas que las contienen para emplear en el tratamiento de miomas y cancer de mamas.

Legal Events

Date Code Title Description
FB Suspension of granting procedure